Health Economics›Malignant solid neoplasm SMO-mutated or PTCH-1-mutated (Hedgehog)›All lines of therapy

All lines of therapy

Malignant solid neoplasm SMO-mutated or PTCH-1-mutated (Hedgehog) · 1 regimen

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Vismodegib monotherapy Variant #01	SMO\|PTCH-1	R 87 723	540d	—	—	~2	~R 175 447 indirect	—

1 of 1 regimen shown